Ordering
Available Variants1 g
CHA.73470-1g
Price
€30.32
Available – Dispatch in 14 days
5 g
CHA.73470-5g
Price
€100.80
Available – Dispatch in 14 days
25 g
CHA.73470-25g
Price
€417.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 g | CHA.73470-1g | €30.32 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 g | CHA.73470-5g | €100.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 g | CHA.73470-25g | €417.60 |
≥99% (TLC), powder, β-adrenoceptor antagonist
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C16H21NO2 · HCl |
|---|---|
| CAS Number | 318-98-9 |
| Molecular Weight | 295.80 |
| NACRES | NA.77 |
| PubChem Substance ID | 24277796 |
| UNSPSC Code | 12352200 |
| EC Number | 206-268-7 |
| MDL number | MFCD00012558 |
| Beilstein/REAXYS Number | 4164259 |
| Assay | ≥99% (TLC) |
| Form | powder |
| Quality level | 200 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 |
| pcodes | P264 - P270 - P301 + P312 + P330 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | dust mask type N95 (US), Eyeshields, Faceshields, Gloves |
Technical Overview & Applications Use-case context
(±)-Propranolol hydrochloride, with a CAS number of 318-98-9, is a non-selective beta-adrenergic receptor blocker commonly utilized in the management of various cardiovascular conditions, including hypertension, angina pectoris, and arrhythmias. Its mechanism of action involves the competitive inhibition of beta-1 and beta-2 adrenergic receptors, resulting in decreased heart rate, contractility, and cardiac output. As a hydrochloride salt, it exhibits improved solubility and bioavailability, facilitating its administration via oral and parenteral routes. The racemic mixture of propranolol isomers confers a balanced pharmacological profile, with the S-enantiomer being primarily responsible for its beta-blocking activity. With its well-established efficacy and safety profile, (±)-propranolol hydrochloride remains a widely prescribed medication for the treatment of cardiovascular disorders, and its applications continue to expand into other therapeutic areas, including the management of anxiety and performance anxiety disorders.
